138 related articles for article (PubMed ID: 9224309)
1. Long-term followup of all patients with muscle invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region.
Holmäng S; Hedelin H; Anderström C; Johansson SL
J Urol; 1997 Aug; 158(2):389-92. PubMed ID: 9224309
[TBL] [Abstract][Full Text] [Related]
2. Long-term followup of a bladder carcinoma cohort: questionable value of radical radiotherapy.
Holmäng S; Hedelin H; Borghede G; Johansson SL
J Urol; 1997 May; 157(5):1642-6. PubMed ID: 9112495
[TBL] [Abstract][Full Text] [Related]
3. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer.
Tran E; Souhami L; Tanguay S; Rajan R
Am J Clin Oncol; 2009 Aug; 32(4):333-7. PubMed ID: 19381080
[TBL] [Abstract][Full Text] [Related]
4. Radical cystectomy for invasive bladder cancer--a local experience.
Abratt RP; Shepherd LC; Pontin AR; Barnes RD; Ball HS
S Afr J Surg; 1998 Aug; 36(3):87-9; discussion 89-90. PubMed ID: 9810218
[TBL] [Abstract][Full Text] [Related]
5. Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle-invasive carcinoma of the urinary bladder: long term results of a pilot study.
Vikram B; Chadha M; Malamud SC; Hecht H; Grabstald H
Cancer; 1998 Mar; 82(5):918-22. PubMed ID: 9486582
[TBL] [Abstract][Full Text] [Related]
6. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
8. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
9. Can patient selection for bladder preservation be based on response to chemotherapy?
Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
[TBL] [Abstract][Full Text] [Related]
10. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
11. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis.
Koga F; Yoshida S; Kawakami S; Kageyama Y; Yokoyama M; Saito K; Fujii Y; Kobayashi T; Kihara K
Urology; 2008 Aug; 72(2):384-8. PubMed ID: 18455771
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer.
Chung PW; Bristow RG; Milosevic MF; Yi QL; Jewett MA; Warde PR; Catton CN; McLean M; Moore M; Tannock IF; Gospodarowicz MK
Urol Oncol; 2007; 25(4):303-9. PubMed ID: 17628296
[TBL] [Abstract][Full Text] [Related]
13. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
[TBL] [Abstract][Full Text] [Related]
14. [Organ-preserving therapy in invasive bladder carcinoma].
Dunst J; Bornhof C; Altendorf-Hofmann A; Wittekind C; Schrott KM; Sauer R
Dtsch Med Wochenschr; 1992 Nov; 117(47):1783-8. PubMed ID: 1425303
[TBL] [Abstract][Full Text] [Related]
15. Organ-sparing treatment in muscle-invasive bladder cancer.
Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
[TBL] [Abstract][Full Text] [Related]
16. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
[TBL] [Abstract][Full Text] [Related]
17. The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience.
Serretta V; Lo Greco G; Pavone C; Pavone-Macaluso M
J Urol; 1998 Apr; 159(4):1187-91. PubMed ID: 9507829
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow up of patients with invasive bladder carcinoma receiving combined cisplatin-based intra-arterial chemotherapy and radiotherapy.
Mori K; Nomata K; Noguchi M; Eguchi J; Hayashi N; Kanetake H
Int J Urol; 2007 Jul; 14(7):591-4. PubMed ID: 17645599
[TBL] [Abstract][Full Text] [Related]
19. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
[TBL] [Abstract][Full Text] [Related]
20. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
